Business Description
Helix BioPharma Corp
NAICS : 325412
SIC : 3741
ISIN : CA4229101098
Description
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -0.06 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -45.3 | |||||
| 3-Year EPS without NRI Growth Rate | -43.9 | |||||
| 3-Year FCF Growth Rate | -20.4 | |||||
| 3-Year Book Growth Rate | 65.6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.74 | |||||
| 9-Day RSI | 57.11 | |||||
| 14-Day RSI | 54.86 | |||||
| 6-1 Month Momentum % | -12 | |||||
| 12-1 Month Momentum % | -12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.92 | |||||
| Quick Ratio | 0.92 | |||||
| Cash Ratio | 0.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.2 | |||||
| Shareholder Yield % | -11.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -784.9 | |||||
| ROIC % | -3764.87 | |||||
| ROC (Joel Greenblatt) % | -25801.68 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -5.04 | |||||
| EV-to-EBITDA | -5.05 | |||||
| EV-to-FCF | -8.88 | |||||
| Earnings Yield (Greenblatt) % | -19.85 | |||||
| FCF Yield % | -10.98 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Helix BioPharma Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.216 | ||
| Beta | 0.3 | ||
| Volatility % | 51.51 | ||
| 14-Day RSI | 54.86 | ||
| 14-Day ATR (€) | 0.032475 | ||
| 20-Day SMA (€) | 0.5722 | ||
| 12-1 Month Momentum % | -12 | ||
| 52-Week Range (€) | 0.34 - 0.935 | ||
| Shares Outstanding (Mil) | 49.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Helix BioPharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Helix BioPharma Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Helix BioPharma Corp Frequently Asked Questions
What is Helix BioPharma Corp(FRA:HBP0)'s stock price today?
The current price of FRA:HBP0 is €0.54. The 52 week high of FRA:HBP0 is €0.94 and 52 week low is €0.34.
When is next earnings date of Helix BioPharma Corp(FRA:HBP0)?
The next earnings date of Helix BioPharma Corp(FRA:HBP0) is .
Does Helix BioPharma Corp(FRA:HBP0) pay dividends? If so, how much?
Helix BioPharma Corp(FRA:HBP0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers